Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Neuraxis Inc (NRXS)

Neuraxis Inc (NRXS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 29,615
  • Shares Outstanding, K 10,653
  • Annual Sales, $ 2,690 K
  • Annual Income, $ -8,240 K
  • EBIT $ -8 M
  • EBITDA $ -7 M
  • 60-Month Beta 3.13
  • Price/Sales 10.63
  • Price/Cash Flow N/A
  • Price/Book 11.73

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr N/A
See More
  • Average Estimate N/A
  • Number of Estimates N/A
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) N/A

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.21 +22.62%
on 11/20/25
2.83 -4.24%
on 11/28/25
+0.17 (+6.69%)
since 11/04/25
3-Month
2.21 +22.62%
on 11/20/25
3.96 -31.57%
on 10/24/25
+0.25 (+10.07%)
since 09/04/25
52-Week
1.33 +103.76%
on 04/16/25
6.20 -56.29%
on 05/20/25
-0.36 (-11.73%)
since 12/04/24

Most Recent Stories

More News
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain

CARMEL, Ind., Dec. 01, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives

CARMEL, Ind., Nov. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues

CARMEL, Ind., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025

CARMEL, Ind., Nov. 04, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population

Achieves significant expansion of NeurAxis’ total addressable market Clearance now includes patients aged “8 years and older” Expanded age indication will utilize the upcoming January 1 st...

NRXS : 2.71 (-2.52%)
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

CARMEL, Ind., Sept. 18, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth

Shares of NeurAxis, Inc. NRXS have lost 0.8% since the company reported its earnings for the quarter ended June 30, 2025. This compares unfavorably with the S&P 500 Index’s 1.2% gain during the same...

NRXS : 2.71 (-2.52%)
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues

CARMEL, Ind., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for...

NRXS : 2.71 (-2.52%)
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025

CARMEL, Ind., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (“NeurAxis,” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies addressing...

NRXS : 2.71 (-2.52%)
NeurAxis Announces New Medical Policy Coverage with Two Health Insurers, Adding 700,000 Covered Lives

NRXS : 2.71 (-2.52%)

Business Summary

NeurAxis, Inc. is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis, Inc. is based in CARMEL, Ind.

See More

Key Turning Points

3rd Resistance Point 2.89
2nd Resistance Point 2.86
1st Resistance Point 2.78
Last Price 2.71
1st Support Level 2.67
2nd Support Level 2.64
3rd Support Level 2.56

See More

52-Week High 6.20
Fibonacci 61.8% 4.34
Fibonacci 50% 3.76
Fibonacci 38.2% 3.19
Last Price 2.71
52-Week Low 1.33

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar